Get started
Author

Hope Qamoos

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
2018 · Steven G. DuBois, Theodore W. Laetsch, et al. · Cancer · 138
PDF
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study
2022 · Carrie L. Kitko, Mukta Arora, et al. · Journal of Clinical Oncology · 104
PDF
Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
2019 · Cornelis Martinus van Tilburg, Steven G. DuBois, et al. · Journal of Clinical Oncology · 20
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
2024 · John O. Mascarenhas, Viola Maria Popov, et al. · Blood · 17
PDF
Evaluating Barriers and Opportunities in Delivering High-Quality Oncology Care in a Resource-Limited Setting Using a Comprehensive Needs Assessment Tool
2018 · Chika R. Nwachukwu, Omobola Mudasiru, et al. · Journal of Global Oncology · 13
S210: an Open-label, Global, Phase (ph) 1b/2 Study Adding Navtemadlin (nvtm) to Ruxolitinib (rux) in Patients (pts) With Primary or Secondary Myelofibrosis (mf) Who Have a Suboptimal Response to Rux
2023 · John Mascarenhas, Tania Jain, et al. · HemaSphere · 11
Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment
2021 · Stephanie J. Lee, Mukta Arora, et al. · Blood · 11
An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib
2020 · John Mascarenhas, Alessandro M. Vannucchi, et al. · Blood · 10
Activity of larotrectinib in patients with TRK fusion GI malignancies
2018 · M. Nathenson, G. Demetri, et al. · Annals of Oncology · 9
KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti–PD-1/L1 immunotherapy.
2020 · Michael K.K. Wong, Ciara Marie Kelly, et al. · Journal of Clinical Oncology · 8
S214: Disease-modifying Activity of Navtemadlin (nvtm) Correlated With Survival Outcomes in Janus Kinase Inhibitor (jaki) Relapsed or Refractory (r/r) Myelofibrosis (mf) Patients (pts)
2023 · Pankit Vachhani, Andrew Perkins, et al. · HemaSphere · 4
A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)
2020 · Peter Hillmen, Hope Qamoos, et al. · Blood · 2
A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers.
2019 · Steven G. DuBois, Catherine Michelle Albert, et al. · Journal of Clinical Oncology · 2
P1038: Tl-895, a First-in-class, Covalent Bruton Tyrosine Kinase Inhibitor (btki) for the Treatment of Myelofibrosis (mf) Patients (pts) With Severe Thrombocytopenia (platelets (plts) <50 K/ul)
2023 · Michael Loschi, Laszlo Rejto, et al. · HemaSphere · 1
Pb2198: Trial in Progress: an Open-label, Global, Multicenter, Phase 1b/2 Study of Tl-895, a Bruton’s Tyrosine Kinase Inhibitor (btki), Added to Ruxolitinib (rux) in Patients (pts) With Myelofibrosis (mf)
2023 · Francesca Palandri, Stefanie Gröpper, et al. · HemaSphere
Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment
2022 · Carrie L. Kitko, Mukta Arora, et al. · Transplantation and Cellular Therapy
Works count: 16
Citation count: 350
H-index: 9
I10-index: 8
Year
Topic
Type